Accelerating the speed of innovative anti-tumor drugs to first-in-human trials incorporating key de-risk strategies

Pharmaceutical companies have recently focused on accelerating the timeline for initiating first-in-human (FIH) trials to allow quick assessment of biologic drugs. For example, a stable cell pool can be used to produce materials for the toxicology (Tox) study, reducing time to the clinic by 4–5 mont...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yuqi Wang, Quan Quan, Camille Gleason, Helin Yu, Lujia Peng, Yanshen Kang, Ling Jiang, Kailun Wu, Jie Pan, Moxiyele Bao, Qing Zhu, Meiqi Yi, Ming Fang, Yue Zheng, Ling Qiu, Bin Xu, Xiang Li, Jinfeng Song, Jiamu Sun, Zheng Zhang, Zijun Su, Jara Lin, Yuanyuan Xie, April Xu, Xiling Song, Chichi Huang, Zhirong Shen, Lai Wang, Jing Song
Format:	Artikel
Sprache:	Englisch
Veröffentlicht:	Taylor & Francis Group 2023-12-01
Schriftenreihe:	mAbs
Schlagworte:	Acceleration characterization CMC first-in-human monoclonal antibody risk mitigation
Online-Zugang:	https://www.tandfonline.com/doi/10.1080/19420862.2023.2292305
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!

Accelerating the speed of innovative anti-tumor drugs to first-in-human trials incorporating key de-risk strategies

Ähnliche Einträge